key: cord-0944029-pttgcjbq authors: Zhang, Ji-Yuan; Wang, Xiang-Ming; Xing, Xudong; Xu, Zhe; Zhang, Chao; Song, Jin-Wen; Fan, Xing; Xia, Peng; Fu, Jun-Liang; Wang, Si-Yu; Xu, Ruo-Nan; Dai, Xiao-Peng; Shi, Lei; Huang, Lei; Jiang, Tian-Jun; Shi, Ming; Zhang, Yuxia; Zumla, Alimuddin; Maeurer, Markus; Bai, Fan; Wang, Fu-Sheng title: Single-cell landscape of immunological responses in COVID-19 patients date: 2020-07-24 journal: bioRxiv DOI: 10.1101/2020.07.23.217703 sha: 02b5ecd83d3dec63889c2a8299183be955dd9119 doc_id: 944029 cord_uid: pttgcjbq In COVID-19 caused by SARS-CoV-2 infection, the relationship between disease severity and the host immune response is not fully understood. Here we performed single-cell RNA sequencing in peripheral blood samples of five healthy donors and 13 COVID-19 patients including moderate, severe and convalescent cases. Through determining the transcriptional profiles of immune cells, coupled with assembled T cell receptor and B cell receptor sequences, we analyzed the functional properties of immune cells. Most cell types in COVID-19 patients showed a strong interferon-alpha response, and an overall acute inflammatory response. Moreover, intensive expansion of highly cytotoxic effector T cell subsets, such as CD4+ Effector-GNLY (Granulysin), CD8+ Effector-GNLY and NKT CD160, was associated with convalescence in moderate patients. In severe patients, the immune landscape featured a deranged interferon response, profound immune exhaustion with skewed T cell receptor repertoire and broad T cell expansion. These findings illustrate the dynamic nature of immune responses during the disease progression. In COVID-19 caused by SARS-CoV-2 infection, the relationship between disease severity and the host immune response is not fully understood. Here The coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes a spectrum of illness from mild to severe disease and death 1 . Though SARS-CoV-2 like SARS-CoV uses angiotensin-converting enzyme 2 (ACE2) as its receptor for entry in target cells 2, 3 , the viral shedding pattern is different between the two viruses. The SARS-CoV-2 viral load is detectable during the presymptomatic stage [4] [5] [6] and peaks soon after disease onset 7-9 , which is significantly earlier than that of SARS-CoV 10 11, 12 . The majority of the patients exhibit mild to moderate symptoms, up to 15% progress to severe pneumonia and approximately 5% eventually develop acute respiratory distress syndrome (ARDS) and/or multiple organ failure 11 . Higher fatality rates have been observed in elderly individuals with co-morbidities and those who are immunocompromised [13] [14] [15] [16] . Since there are no effective drugs or vaccines available at this time against SARS-CoV-2, there is an urgent need to better understand the host immune response during disease in order to better devise prognostic and diagnostic markers, and to design appropriate therapeutic interventions for patients with severe disease presentation. Viral infection and the antiviral host immune response interact in vivo and shape disease severity as well as clinical outcomes, especially during acute viral infection. Therefore, the immunopathology of COVID-19 has received much attention. Immune responses in a COVID-19 patient with moderate disease presentation 17 , show that a robust cellular and humoral immune response can be elicited upon acute SARS-CoV-2 infection. However, it remained unknown how the uncontrolled innate and impaired adaptive immune responses were associated with pulmonary tissue damage. COVID-19 patients with severe disease presentation showed pronounced lymphopenia and elevation of serum pro-inflammatory cytokines 18, 19 . We recently reported a fatal case where significant interstitial lymphocytic infiltrates in both lung tissues and overactivation of T cells in peripheral blood were observed 20 . More recently, inflammatory FCN1 + macrophages were found to replace FABP4 + macrophages in the bronchoalveolar lavage fluid from severe SARS-CoV-2 infected patients, whereas highly expanded and functional competent tissue resident clonal CD8 + T cells were observed in moderate patients with SARS-CoV-2 infection 21 To characterize the immunological features of patients with COVID-19, we performed droplet-based scRNA-seq (10X Genomics) to study the transcriptomic profiles of peripheral blood mononuclear cells (PBMCs) from 13 patients and five healthy donors (HD: n=5) as controls (Fig. 1a) . The 13 COVID-19 patients were classified into three clinical conditions: moderate (Moderate: n=7), severe (Severe: n=4) and convalescent (Conv: n=6 of whom four were paired with moderate cases) (Fig. 1a, b, Table 1 and Supplementary Fig. 1 ). The clinical characteristics and laboratory findings of enrolled patients are detailed in Table 1 LILRA4 + ), platelets (PPBP + ) and hemopoietic stem cells (HSCs: CYTL1 + GATA2 + ). As such, we clearly defined the composition of cell subpopulations in peripheral blood. To reveal the differences in cell compositions across three conditions (Moderate, Severe, and Conv), and to compare with that in HD, we calculated the relative percentage of the 14 major cell types in the PBMCs of each individual on the basis of scRNA-seq data ( Fig. 2a-d) . The relative percentage of activated T cluster peaked in moderate patients and did not return to the normal level, even at convalescence. Of note, the relative abundance of naive T cells, MAIT cells, and Mono DCs decreased with the disease severity, and these populations later restored in Conv patients (Fig. 2d ). In contrast, the relative percentage of Pro T cells, plasma B cells, CD14 + Mono, and platelets increased with disease severity and later declined in Conv patients (Fig. 2d) . The massive increase of CD14 + Mono in patients with severe disease was in accordance with a recent study demonstrating that inflammatory monocytes, induced by pathogenic T cells, incite the inflammatory storm in COVID-19 22 . Next, to investigate the antiviral and pathogenic immune responses during SARS-CoV-2 infection, we evaluated the expression levels of two important pathways (Gene Ontology biological process terms: Response to interferon alpha, and Acute inflammatory response) in major cell types across four conditions. We found that the response to interferon alpha was uniformly and significantly up-regulated in all major cell types from the PBMCs of COVID-19 patients and showed the highest value in almost every major cell type in severe patients, with the exception of plasma B cells, in which the interferon alpha response was greatest in moderate patients (Fig. 2e ). In addition, with the exception of Pro T cells, the acute inflammatory response showed consistent and significant differences across conditions in the selected cell types. Several cell types showed trends in the acute inflammatory response that roughly corresponded with disease severity, including activated T, γδT, NK and CD16 + mono ( Fig. 2e) . Moreover, the plasma levels of Type I IFN, IFN-γ and other inflammatory cytokines displayed the highest levels in severe patients ( Supplementary Fig. 2c) . These results suggest a strong overall pro-inflammatory response in COVID-19 patients (Fig. 2e ). To further investigate the transcriptomic changes of innate immune cells (Fig. 3a, b) after SARS-CoV-2 infection, we compared the expression patterns of the Moderate or Severe condition with that of the HD condition in CD14 + and CD16 + monocytes. We found that the significantly differentially expressed genes (DEGs) were involved in interferon responses, myeloid leukocyte activation, cytokine production and NF-κB signaling pathway in COVID-19 patients (Fig. 3c, d) . In addition, more DEGs in monocytes from the Severe condition were enriched in molecule metabolic and catabolic processes, as well as cytokine secretion ( Supplementary Fig. 3a ). For NK cells, similar to monocytes, DEGs associated with interferon responses, cytokine production, NF-κB signaling pathway and leukocyte cytotoxicity were significantly enriched in COVID-19 patients (Fig. 3e, f) , suggesting a consistent response by innate immune cells to SARS-CoV-2 infection. Furthermore, in comparison with moderate patients, the DEGs of the NK cells of the Severe condition, such as ITGB2, CCL5 and CXCR2, were more closely related to migration associated processes ( Supplementary Fig. 3b , c). In line with the DEG enrichment results, we found that monocytes and NK cells both showed significantly up-regulated IFN and acute inflammatory responses after SARS-CoV-2 infection, especially in severe patients (Fig 2e) . Levels of cellular apoptosis and migration were also up-regulated in both monocytes and NK cells compared to the HD condition (Fig. 3g) . Unlike the comparable apoptosis levels in monocytes and NK cells, the innate immune cells in severe patients were more prone to migration than those in moderate patients ( Fig. 3g and Supplementary Fig. 3c ). These results suggest that most innate immune cell types in COVID-19 patients show strong interferon responses. To characterize changes in individual T cell subsets among individuals across four conditions, we sub-clustered T cells from PBMCs and obtained 12 subsets according to the expression and distribution of canonical T cell markers (Fig. 4a, b) : 6 subtypes of CD4 + T cells (CD3E + CD4 + ), three subtypes of CD8 + T cells (CD3E + CD8A + ) and 3 subtypes of NKT cells (CD3E + CD4 -CD8A -TYROBP + ). Of the six subtypes of CD4 + T cell clusters, in addition to naive CD4 + T (CD4 + Naive: CCR7 + SELL + ), memory CD4 + T (CD4 + Memory: S100A4 + GPR183 + ), effector memory CD4 + T (CD4 + Effector Memory: S100A4 + GPR183 + GZMA + ) and regulatory T (Treg: FOXP3 + IL2RA + ) subtypes, we defined two effector CD4 + T subtypes, CD4 + Effector-GZMK and CD4 + Effector-GNLY. The CD4 + Effector-GNLY cluster was characterized by high expression of genes associated with cytotoxicity, including NKG7, GZMA, GZMB, GZMH and GNLY, while the CD4 + Effector-GZMK cluster showed a relatively high expression level of the GZMK gene, but low expression of other cytotoxic genes ( Fig. 4b and Supplementary Fig. 4a, b) . Furthermore, CD4 + Effector-GNLY cells showed high expression of TBX21, implying that they were Type I T helper (TH1) liked cells ( Supplementary Fig. 4c ). In contrast, CD4 + Effector-GZMK and CD4 + Effector Memory harbored Type Ⅱ T helper (TH2) liked features with high expression of GATA3 ( Supplementary Fig. 4c ). The three subtypes of CD8 + T cell clusters included naive CD8 + T subset (CD8 + Naive: CCR7 + SELL + ), and two effector CD8 + T subsets (CD8 + Effector-GZMK and CD8 + Effector-GNLY), which both had high expression levels of GZMA and NKG7. In detail, CD8 + Effector-GZMK uniquely expressed GZMK, whereas CD8 + Effector-GNLY showed relatively high expression levels of GZMB/H and GNLY ( Fig. 4b and Supplementary Fig. 4a, b) . The three subsets of NKT cell clusters were defined as naive NKT cells (NKT Naive: CCR7 + SELL + ), CD56 + NKT cells (NKT CD56) and CD160 + NKT cells (NKT CD160) (Fig. 4a, b) . To gain insights into features in T cell subsets, we evaluated the distribution of each cluster across four conditions ( Fig. 4c and Supplementary Fig. 4d, e) . Notably, the proportions of naive state T subsets including CD4 + Naive, CD4 + Memory, CD4 + Effector Memory, Treg, CD8 + Naive and NKT Naive subsets, decreased in COVID-19 patients in comparison with HDs ( Fig. 4c and Supplementary Fig. 4d ). Even in the Conv condition, the proportions of CD4 + Naive, CD8 + Naive and Treg clusters did not restore to the levels of HDs ( Fig. 4c and Supplementary Fig. 4d ). In contrast, the proportions of active state T subsets, including CD4 + Effector-GNLY, CD8 + Effector-GNLY, NKT CD56 and NKT CD160 subsets, increased in COVID-19 patients, and these cytotoxic subsets were present in high proportions even in Conv patients (Fig. 4c) . Of particular interest, the CD4 + Effector-GNLY subset was almost absent in HDs but highly enriched in moderate, severe and Conv patients. In addition, the abundance of the NKT CD160 subset was significantly reduced in severe patients as compared to moderate patients. We then evaluated the cytotoxicity and exhaustion scores of different effector state T subsets across four conditions ( Fig. 4d and Supplementary Fig. 4f ). The CD4 + Effector-GNLY, CD8 + Effector-GNLY, NKT CD56 and NKT CD160 subsets showed higher cytotoxicity scores than those of the other subsets. Within these highly cytotoxic clusters, healthy donors all had the lowest cytotoxicity scores, whereas the Moderate condition showed the highest cytotoxic state, with the exception of the CD4 + Effector-GNLY subset (Fig. 4d , e and Supplementary Fig. 4f) . Meanwhile, the CD4 + Effector-GZMK, CD8 + Effector-GZMK and NKT CD160 clusters showed higher exhaustion scores than those of the other subsets. Within these highly exhausted subsets, healthy donors all had the lowest exhaustion scores, while severe patients showed the most exhausted state (Fig. 4d , e and Supplementary Fig. 4f ), in agreement with previous functional studies which examined CD8 + T cells from severe patients and found highly exhausted status and functional impairment 23 . To further investigate differential transcriptomic changes in T cells after SARS-CoV-2 infection, we compared the expression profiles of effector T cells (excluding CD4 + Naive, CD4 + Memory, CD8 + Naive and NKT Naive clusters) between the Moderate or Severe and HD conditions. We observed that DEGs up-regulated in COVID-19 patients were involved in processes including interferon responses, cytokine production, cell killing, leukocyte cell-cell adhesion and cytoskeleton organization (Fig. 4f , g and Supplementary Fig. 4i ). In addition, using an apoptosis and migration scoring system, we observed that T cells in severe patients likely underwent migration and apoptosis (Fig. 4h , i and Supplementary Fig. 4g , h). Significant activation of cell death and migration pathways in the PBMCs of severe patients suggests that cell death and lymphocytes migration may be associated with lymphopenia, a common phenomenon observed in severe COVID-19 patients 18, 19, 24 . Next, to gain insight into the clonal relationship among individual T cells and usage of V(D)J genes across four conditions, we reconstructed TCR sequences from the TCR sequencing. Briefly, there were more than 70% of cells in all subsets with matched TCR information except for the three NKT subsets (Fig. 5a, b) . First, compared to the HDs, sequences were different across four conditions (Fig. 5h) . The Moderate and Conv conditions shared some CDR3 sequences because four samples from these conditions were paired. The usage percentage of the top 10 CDR3 sequences in the HD condition was lower and more balanced compared to those of the other three conditions. Of note, we discovered a different usage of V(D)J genes with decreased diversity in COVID-19 patients, which was more pronounced in TRA genes (Fig. 5i ). We also identified overrepresentation of TRAJ39 and TRAJ43 in severe patients compared to moderate and Conv patients (Fig. 5g) . The preferred TRBJ gene in severe patients was TRBJ1-1, whereas TRBJ2-1 was preferred in moderate and Conv patients (Fig. 5i) . The selective usage of V(D)J genes indicates that different immunodominant epitopes may drive the molecular composition of T cell responses and may be associated with SARS-CoV-2 specific infection. To trace the dynamic changes of different B subtypes, we sub-clustered B cells into six subsets according to the expression and distribution of canonical B cell markers (Fig. 6a , b and Supplementary Fig. 6a ). We identified one naive B subset (Naive B; We also reconstructed B cell receptor (BCR) sequences from BCR sequencing and analyzed the state of B cell-receptor (BCR) clonal expansion. Briefly, the detection percentage of BCRs was more than 75% in each cluster (Fig. 7a, b) . We found that B cells from severe patients showed obvious clonal expansions ( Fig. 7c and Supplementary Fig. 6d ) than other three conditions, indicating that B cell activity and humoral immune responses were strongly activated in severe patients, reminiscent of previous observation that higher antibody titers are associated with worse clinical outcomes 25-27 . This raises the concern that, pathogen-directed antibodies can promote disease pathology, resulting in antibody-dependent enhancement (ADE) similar to that observed in SARS 28 . Conditions are shown in different colors. Horizontal lines represent median values, with whiskers extending to the farthest data point within a maximum of 1.5 × interquartile range. All differences with P < 0.01 are indicated. **P < 0.001; ***P < 0.0001; two-sided unpaired Dunn's (Bonferroni) test. Conditions are shown in different colors. Horizontal lines represent median values, with whiskers extending to the farthest data point within a maximum of 1.5 × interquartile range. All differences with P < 0.01 are indicated. **P < 0.001; ***P < 0.0001; two-sided unpaired Dunn's (Bonferroni) test. values, with whiskers extending to the farthest data point within a maximum of 1.5 × interquartile range. All differences with P < 0.05 are indicated; two-sided paired Mann-Whitney U test. i, The expression levels of two GO biological process terms across clusters derived from HD (n=5), Moderate (n=7), Severe (n=4) and Conv (n=6) samples. Horizontal lines represent median values, with whiskers extending to the farthest data point within a maximum of 1.5 × interquartile range. All differences with P < 0.01 are indicated. **P < 0.001; ***P < 0.0001; two-sided unpaired Dunn's (Bonferroni) test. Error bars represent ± s.e.m. for five healthy donors and 13 patients. All differences with P < 0.05 are indicated; two-sided unpaired Mann-Whitney U test. h, The top ten CDR3 usages are shown. Each bar is colored by condition identity. Shared CDR3 sequences are in a red font. i, TRA/B rearrangements differences across four conditions. The colors indicate the usage percentage of specific V-J gene pairs. Critically ill cases who were grouped in the Severe condition in this study generally required mechanical ventilation and exhibited respiratory failure, septic shock, and/or multiple organ dysfunction/failure that required monitoring and treatment in the ICU. One case in Severe group died during the study period. The patients in convalescent group met the discharge criteria as follows: afebrile for more than 3 days, resolution of respiratory symptoms, substantial improvement of chest CT images, and 2 consecutive negative reverse transcription-quantitative polymerase chain reaction (RT-qPCR) tests for viral RNA in respiratory tract swab samples obtained at least 24 hours apart. This study was approved by the ethics committee of the hospital and written informed consents or the telephone call permissions were obtained from each patient or their guardian in the very difficult conditions of early COVID-19 pandemic. The clinical data and disease course of the 13 patients are shown in Table 1 and Fig. 1 ). The throat swab, sputum from the upper respiratory tract and blood were collected from patients at various time-points after hospitalization. Sample collection, processing, and laboratory testing complied with WHO guidance. Viral RNA was For each sample, cell viability exceeded 90%. To compare cell types and proportions across four conditions, we employed the integration methods described at (https://satijalab.org/seurat/v3.0/integration.html) 44 . The Seurat package (Version 3.0.0) was used to assemble multiple distinct scRNA-seq datasets into an integrated and unbatched dataset. In brief, we identified 2000 features with high cell-to-cell variation as described above. Second, we identified "anchors" between individual datasets with the FindIntegrationAnchors function and inputted these "anchors" into the IntegrateData function to create a "batch-corrected" expression matrix of all cells, which allowed cells from different datasets to be integrated and analyzed together. B cells and plasma cells were extracted from PBMCs. Next, these major cell types were integrated for further sub-clustering. After integration, genes were scaled to unit variance. Scaling, PCA and clustering were performed as described above. Naive and Activated T cells in PBMCs were also extracted and sub-clustered using the procedure used for B cells. After non-linear dimensional reduction and projection of all cells into twodimensional space by UMAP, cells clustered together according to common features. The FindAllMarkers function in Seurat was used to find markers for each of the identified clusters. Clusters were then classified and annotated based on expressions of canonical markers of particular cell types. Clusters expressing two or more canonical cell-type markers were classified as doublet cells and excluded from further analysis. Differential gene expression testing was performed using the FindMarkers function in Seurat with parameter "test.use=wilcox" by default, and the Benjamini-Hochberg method was used to estimate the false discovery rate (FDR). DEGs were filtered using a minimum log2(fold change) of 0.5 and a maximum FDR value of 0.01. Enrichment analysis for the functions of the DEGs was conducted using the Metascape webtool (www.metascape.org). Gene sets were derived from the GO Biological Process Ontology. We used cell scores to evaluate the degree to which individual cells expressed a certain pre-defined expression gene set [45] [46] [47] . The cell scores were initially based on the average expression of the genes from the pre-defined gene set in the respective cell. Each unique IGH(s)-IGK/IGL(s) pair was defined as a clonotype. If one clonotype was present in at least two cells, cells harboring this clonotype were considered clonal, and the number of cells with such pairs indicated the degree of clonality of the clonotype. prevalent BCR clonotypes were projected on UMAP plots. Plasma levels of IFN-γ, IL-6, IL-18, MCP-1, MIP-1α and IP-10 were evaluated by using an Aimplex kit (Beijing Quantobio, China) following manufacturer's instructions. Type I IFN, represented by IFN-β, was detected by ELISA kit (Cat. EK1236, Multi Sciences, China) according to the manufacture's protocols. All samples were performed in duplicate. The statistical tools, methods and threshold for each analysis are explicitly described with the results or detailed in the Figure Legends or Methods sections. The raw sequence data reported in this paper have been deposited in the Genome S09 S10 S11 S12 S13 S14 S15 S16 S17 TRAV1 2 TRAV12 2 TRAV12 3 TRAV16 TRAV20 TRAV23DV6 TRAV29DV5 TRAV30 TRAV35 TRAV38 2DV8 TRAV40 TRAV41 TRAV8 2 TRAV9 2 TRBV10 1 TRBV10 3 TRBV12 4 TRBV19 TRBV2 TRBV20 1 TRBV27 TRBV28 TRBV3 1 TRBV4 1 TRBV4 3 TRBV5 1 TRBV5 4 TRBV6 6 TRBV7 2 TRBV7 9 TRBV9 TRAJ11 TRAJ20 TRAJ23 TRAJ26 TRAJ27 TRAJ33 TRAJ34 TRAJ38 TRAJ39 TRAJ43 TRAJ45 TRAJ47 TRAJ48 TRAJ57 TRBJ1 1 TRBJ1 2 TRBJ1 5 TRBJ2 1 TRBJ2 3 TRBJ2 5 TRAV1 2 TRAV12 2 TRAV12 3 TRAV16 TRAV20 TRAV23DV6 TRAV29DV5 TRAV30 TRAV35 TRAV38 2DV8 TRAV40 TRAV41 TRAV8 2 TRAV9 2 TRBV10 1 TRBV10 3 TRBV12 4 TRBV19 TRBV2 TRBV20 1 TRBV27 TRBV28 TRBV3 1 TRBV4 1 TRBV4 3 TRBV5 1 TRBV5 4 TRBV6 6 TRBV7 2 TRBV7 9 TRBV9 TRAJ11 TRAJ20 TRAJ23 TRAJ26 TRAJ27 TRAJ33 TRAJ34 TRAJ38 TRAJ39 TRAJ43 TRAJ45 TRAJ47 TRAJ48 TRAJ57 TRBJ1 1 TRBJ1 2 TRBJ1 5 TRBJ2 1 TRBJ2 3 TRBJ2 5 TRBJ2 7 0 1 2 3 4 Conv TRAV1 2 TRAV12 2 TRAV12 3 TRAV16 TRAV20 TRAV23DV6 TRAV29DV5 TRAV30 TRAV35 TRAV38 2DV8 TRAV40 TRAV41 TRAV8 2 TRAV9 2 TRBV10 1 TRBV10 3 TRBV12 4 TRBV19 TRBV2 TRBV20 1 TRBV27 TRBV28 TRBV3 1 TRBV4 1 TRBV4 3 TRBV5 1 TRBV5 4 TRBV6 6 TRBV7 2 TRBV7 9 TRBV9 TRAJ11 TRAJ20 TRAJ23 TRAJ26 TRAJ27 TRAJ33 TRAJ34 TRAJ38 TRAJ39 TRAJ43 TRAJ45 TRAJ47 TRAJ48 TRAJ57 TRBJ1 1 TRBJ1 2 TRBJ1 5 TRBJ2 1 TRBJ2 3 TRBJ2 5 TRBJ2 7 0 1 2 3 4 Severe TRAV1 2 TRAV12 2 TRAV12 3 TRAV16 TRAV20 TRAV23DV6 TRAV29DV5 TRAV30 TRAV35 TRAV38 2DV8 TRAV40 TRAV41 TRAV8 2 TRAV9 2 TRBV10 1 TRBV10 3 TRBV12 4 TRBV19 TRBV2 TRBV20 1 TRBV27 TRBV28 TRBV3 1 TRBV4 1 TRBV4 3 TRBV5 1 TRBV5 4 TRBV6 6 TRBV7 2 TRBV7 9 TRBV9 TRAJ11 TRAJ20 TRAJ23 TRAJ26 TRAJ27 TRAJ33 TRAJ34 TRAJ38 TRAJ39 TRAJ43 TRAJ45 TRAJ47 TRAJ48 TRAJ57 TRBJ1 1 TRBJ1 2 TRBJ1 5 TRBJ2 1 TRBJ2 3 TRBJ2 5 TRBJ2 C C R 7 S E LL LE F 1 T C F 7 P R F 1 IF N G G N LY N K G 7 G Z M B G Z M A G Z M H K LR K 1 K LR B 1 K LR D 1 C T S W C S T 7 F C G R 3A LA G 3 T IG IT P D C D 1 C T LA 4 H A V C R 2 T O X A novel coronavirus from patients with pneumonia in China Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, China Transmission of 2019-nCoV infection from an asymptomatic contact in Germany Temporal dynamics in viral shedding and transmissibility of COVID SARS-CoV-2 viral load in upper respiratory specimens of infected patients Virological assessment of hospitalized patients with COVID-2019 Viral load of SARS-CoV-2 in clinical samples Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study COVID-19: immunopathology and its implications for therapy The trinity of COVID-19: immunity, inflammation and intervention Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China Liver injury in COVID-19: management and challenges Clinical features of patients infected with 2019 novel coronavirus in Wuhan Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19 Clinical and immunological features of severe and moderate coronavirus disease 2019 Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study Pathological findings of COVID-19 associated with acute respiratory distress syndrome Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 Pathogenic T cells and inflammatory monocytes incite References Integrating singlecell transcriptomic data across different conditions, technologies, and species Comprehensive integration of single-cell data Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer 2 NA NA NA NA NA Prothrombin time We thank the study participants who provided blood samples, and Chun-Bao Zhou, Jin-Hong Yuan for flow cytometry analysis. Jun Hou provided guidance for safely handling *** Cytotoxicity The authors declare no competing interests.